📜Ethyl 6,7-Dihydro-5,8-Dimethyl-9-Fluoro-1-Oxo-1H,5H-Benzo[i,J]Quinolizine-2-Carboxylate 反应生成 依巴沙星 参考文献:Process For 标题:Process For 摘要:一种制备抗微生物药物6,7-二氢-9-氟-5,8-二甲基-1-氧代-1H,5H-苯并[i,J]喹啉-2-羧酸的工艺,以6-氟-2-甲基喹啉为起始物质.还公开了一种合成中间体.
专利号:US-11332444-B2 优先权日:2018-04-25 标题:Method for the hydrolysis of quinolonecarboxylic esters 发明人:FEY PETER; BERWE MATHIAS; WIRTHS Joerg; WISCHNAT RALF; LONGERICH MARKUS; DIETZEL ANTJE 权利人:BAYER ANIMAL HEALTH GMBH 摘要:Quinolonecarboxylic esters of the general formula (II) are hydrolyzed to quinolonecarboxylic acids of the general formula (I):The method comprises the step A):A) reacting compounds of the formula (II) with a mixture comprising acetic acid, sulfuric acid and waterIn step A), ≥30 to ≤40 mol of acetic acid, ≥0.3 to ≤1 mol of sulfuric acid and ≥0.9 to ≤2.5 mol of water are used per mole of compounds of the formula (II). The method is particularly suitable for the synthesis of the intermediate (I) in the synthesis of pradofloxacin.
专利号:US-9693999-B2 优先权日:2011-01-26 标题:Small molecule RNase inhibitors and methods of use 发明人:DUNMAN PAUL M; OLSON PATRICK D; CHILDERS WAYNE 权利人:UNIV ROCHESTER; UNIV NEBRASKA; Temple University—Of the Commonwealth System of Higher Education 摘要:Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.
专利号:WO-2009056955-A1 优先权日:2007-10-30 标题 :Amine-bearing phospholipids (abps), their synthesis and use 发明人:ZUMBUEHL ANDREAS 权利人:UNIV BASEL; ZUMBUEHL ANDREAS 摘要:Disclosed herein are amine-bearing phospholipids (ABP). The ABPs display many properties and functionalities of naturally occurring phospholipids, but also new properties and functionalities, such as the ability to polymerize while maintaining structural integrity, that may supplement or expand the functionalities of naturally occurring phospholipids.
专利号:US-9868747-B2 优先权日:2014-02-18 标题:Marinopyrrole derivatives and methods of making and using same 发明人:LI RONGSHI; SEBTI SAID; LIU YAN; QIN YONG; SONG HAO; CHENG CHUNWEI 权利人:H LEE MOFFITT CANCER CT & RES; CHONGQING ZEIN PHARMACEUTICAL CO LTD 摘要:Marinopyrrole derivatives and methods for their synthesis and use are described herein. Novel cyclic and symmetric marinopyrroles with triazole substituents having antibacterial activity against resistant bacterial strains, such as MRSA are introduced. Also provided are methods of using the compounds for treating or preventing cancer and/or microbial infections.
专利号:US-9907753-B2 优先权日:2010-03-19 标 题 :Lipid vesicle compositions and methods of use 发明人:IRVINE DARRELL J; MOON JAEHYUN 权利人:MASSACHUSETTS INST TECHNOLOGY 摘要:The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.
专利号:JP-H07300461-A 优先权日:1986-01-22 标题 :Intermediate for synthesis of 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid and process for producing the same
1. Horspool LJ, van Laar P, van den Bos R, Mawhinney I. Treatment of canine pyoderma with ibafloxacin and marbofloxacin--fluoroquinolones with different pharmacokinetic profiles. J Vet Pharmacol Ther. 2004 Jun;27(3):147-53. doi: 10.1111/j.1365-2885.2004.00561.x. 158(7):236-7. doi: 10.1136/vr.158.7.236.
合成参考文献
参考文献:10.1046/j.1365-2885.2002.00361.x 摘要:Coulet M, Van Borssum Waalkes M, Leeuwenkamp OR, Cox P, Lohuis J. Pharmacokinetics of ibafloxacin following intravenous and oral administration to healthy Beagle dogs. J Vet Pharmacol Ther. 2002 Apr;25(2):89–97. doi: 10.1046/j.1365-2885.2002.00361.x. 参考文献:10.1111/j.1365-2885.2004.00561.x 摘要:Horspool LJ, van Laar P, van den Bos R, Mawhinney I. Treatment of canine pyoderma with ibafloxacin and marbofloxacin--fluoroquinolones with different pharmacokinetic profiles. J Vet Pharmacol Ther. 2004 Jun;27(3):147–53. doi: 10.1111/j.1365-2885.2004.00561.x.